Virtual R&D Day

October, 30 2023

Review of Results from Phase 1b Trial of VYN201 for the Treatment of Vitiligo, Preclinical Data for VYN202 and Development Plans for VYN201 and VYN202 Join us for a virtual R&D Day with VYNE Therapeutics. The event will focus on the therapeutic potential of VYNE’s novel and proprietary InhiBETTM platform of its bromodomain and extra-terminal (BET) inhibitors, which includes a locally administered pan-BD BET inhibitor (VYN201) and an oral BD2-selective BET inhibitor (VYN202). Date: November 9, 2023 Time: 1:30 PM EST Location: Virtual VYNE management will review the final results from the Phase 1b trial for VYN201 in patients with nonsegmental…

Read More

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

October, 30 2023

Treatment with VYN202 resulted in significant inhibition of key inflammatory biomarkers and substantial resolution of the signs and symptoms of psoriasis and rheumatoid arthritis Following completion of recent financing, VYNE expects to initiate a Phase 1a SAD/MAD clinical trial in Q1 2024, followed by Phase 1b trials in moderate-to-severe plaque psoriasis and in moderate-to-severe adult-onset rheumatoid arthritis in the second half of 2024 Preclinical data and clinical programs to be discussed at R&D Day event on November 9, 2023 BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company…

Read More

VYNE Therapeutics Announces Private Placement of $88 Million

October, 30 2023

Transaction provides $88 million to fund VYNE’s clinical development programs for VYN201 and VYN202 through the end of 2025 BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that the Company has signed a securities purchase agreement with certain healthcare-focused institutional investors for a private placement financing (the “PIPE”) that is expected to result in gross proceeds of $88 million, before deducting placement agent fees and offering expenses. The PIPE was led by Access…

Read More

VYNE Therapeutics Announces Positive Data from Phase 1b Trial for Novel BET Inhibitor VYN201 in Patients with Nonsegmental Vitiligo

October, 30 2023

Clinical proof-of-concept achieved with statistically significant dose dependent reduction in F-VASI score from baseline for the VYN201 1.0% and 2.0% cohorts compared to the 0.5% cohort VYN201 was generally well-tolerated with no clinically relevant treatment emergent adverse events across all dose cohorts Clinical response and rapid onset of action suggest VYN201 has the potential to be the category leader in the treatment of nonsegmental vitiligo VYN201 is expected to advance into a Phase 2b clinical trial in the first half of 2024 BRIDGEWATER, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a…

Read More